Forensic Psychiatry Center, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan
BMJ Case Rep. 2022 Oct 13;15(10):e247734. doi: 10.1136/bcr-2021-247734.
Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is restricted due to the risk of potentially life-threatening side effects, such as agranulocytosis. Although this restriction ensures safety against haematological risks, some patients with refractory schizophrenia who have low neutrophil levels may miss the opportunity to receive clozapine treatment. We herein report the case of a patient with refractory schizophrenia and low neutrophil levels who was successfully initiated on clozapine treatment after the use of several methods for increasing neutrophil levels. These strategies consisted of discontinuation of antipsychotics, treatment with lithium carbonate and adenine, and light exercise before blood testing. Combining these procedures may be an effective option in the treatment of patients with refractory schizophrenia whose neutrophil levels are not sufficient to initiate clozapine.
氯氮平是唯一被证实对难治性精神分裂症有效的药物;然而,由于其可能产生危及生命的副作用(如粒细胞缺乏症)的风险,其应用受到限制。尽管这种限制确保了对血液学风险的安全性,但一些中性粒细胞水平较低的难治性精神分裂症患者可能会错过接受氯氮平治疗的机会。本文报告了一例中性粒细胞水平较低的难治性精神分裂症患者,在使用了几种增加中性粒细胞水平的方法后,成功开始氯氮平治疗。这些策略包括停用抗精神病药物、碳酸锂和腺嘌呤治疗以及在血液检测前进行轻度运动。联合使用这些方法可能是治疗中性粒细胞水平不足以启动氯氮平治疗的难治性精神分裂症患者的有效选择。